Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 11, 2002, Pages 1405-1412

  Hunt, Jay D ^a   Strimas, Anna ^a   Martin, Julie E ^a   Eyer, Marilyn ^a   Haddican, Monica ^a   Luckett, Brian G ^a   Ruiz, Bernardo ^a   Axelrad, T William ^a   Backes, Wayne L ^a   Fontham, Elizabeth T H ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; CYSTEINE; SERINE; VALINE;

ADULT; AGED; ARTICLE; CAUCASIAN; CHROMOSOME MICRODISSECTION; FEMALE; GENE AMPLIFICATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEGRO; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CARCINOGENS; CASE-CONTROL STUDIES; CODON; ENVIRONMENTAL EXPOSURE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LOUISIANA; LUNG NEOPLASMS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; SEQUENCE ANALYSIS, DNA; SPECTRUM ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036846662     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Chen, V. W., Correa, C. N., Wu, X. C., Andrews, P. A., Fontham, E. T. H., Blount, G. A., Jackson, J. E., Lucas. H. F., and Correa, P. Cancer Incidence in Louisiana, 1988-1992 (Cancer in Louisiana, Vol. 8, No. 1). New Orleans, LA: Tumor Registry, 1996
2. Chen, V. W., Wu, X-C., Andrews, P. A., Correa, C. N., and Lucas, H. F. Highlights of cancer incidence in Louisiana, 1988-1992. J. LA State Med. Soc., 149: 119-124, 1997
3. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Chromium, Nickel and Welding. Volume 49. Lyon, France: IARC, 1990
4. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Wood Dust and Formaldehyde. Volume 62. Lyon, France: IARC, 1995
5. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Dry Cleaning, Some Chloronated Solvents and Other Industrial Chemicals. Volume 63. Lyon, France: IARC, 1995
6. Rodenhuis, S. RAS oncogenes and human lung cancer. In: H. I. Pass. J. B. Mitchell, D. H. Johnson, and A. T. Turrisi (eds.), Lung Cancer: Principles and Practice, pp. 73-82. Philadelphia: Lippincott-Raven Publishers, 1996
7. Siegfried, J. M., Gillespie, A. T., Mera, R., Casey, T. J., Keohavong, P., Testa, J. R., and Hunt, J. D. Prognostic value of specific KRAS mutations in lung adenocarcinoma. Cancer Epidemiol. Biomark. Prev., 6: 841-849, 1997
8. Keohavong, P., DeMichele, M. A. A., Melacrinos, A. C., Landreneau, R. J., Weyant, R. J., and Siegfried, J. M. Detection of K-ras mutations in lung carcinomas: Relationship to prognosis. Clin. Cancer Res., 2: 411-418, 1996
9. Keohavong, P., Zhu, D., Melacrinos, A. C., DeMichele, M. A. A., Weyant, R. J., Luketich, J. D., Testa, J. R., Fedder, M., and Siegfried, J. M. Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. Int. J. Cancer, 74: 162-170, 1997
10. Isobe, T., Hiyama, K., Yoshida, Y., Fujiwara, Y., and Yamakido, M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn. J. Cancer Res. (Gann), 85: 1240-1246, 1994
11. Rodenhuis, S., Boerrigter, L., Top, B., Slebos, R. J. C., Mooi, W. J., van't Veer, L., and van Zandwijk, N. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: A prospective study. J. Clin. Oncol., 15: 285-291, 1997
12. Rodenhuis, S., and Slebos, R. J. C. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res., 52 (Suppl.): 2665s-2669s, 1992
13. Silini, E. M., Bosi, F., Pellegata, N. S., Volpato, G., Romano, A., Nazari, S., Tinelli, C., Ranzani, G. N., Solcia, E., and Fiocca, R. K-ras gene mutations: An unfavorable prognostic marker in stage I lung adenocarcinoma. Virchows Arch., 424: 367-373, 1994
14. Rosell, R., Monzo, M., Molina, F., Martinez, E., Pifarre, A., Moreno, I., Mate, J. L., de Anta, J. M., Sanchez, M., and Font, A. K-ras genotypes and prognosis in non-small-cell lung cancer. Ann. Oncol., 6 (Suppl. 3): S15-S20, 1995
15. Fujino, M., Dosaka-Akita, H., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K., and Kawakami, Y. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer (Phila.), 76: 2457-2463, 1995
16. Cho, J. Y., Kim, J. H., Lee, Y. H., Chung, K. Y., Kim, S. K., Gong, S. J., You, N. C., Chung, H. C., Roh., J. K., and Kim, B. S. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer (Phila.), 19: 462-467, 1997
17. Kashii, T., Mizushima, Y., Lima, C. E. Q., Noto, H., Sato, H., Saito, H., Kusajima, Y., Kitagawa, M., Yamamoto, K., and Kobayashi, M. Studies on clinicopathological features of lung cancer patients with K-ras/p53 gene laterations: Comparison between younger and older groups. Oncology (Basel), 52: 219-225, 1995
18. Kern, J. A., Slebos, R. J. C., Top, B., Rodenhuis, S., Lager, D., Robinson, R. A., Weiner, D., and Schwartz, D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Investig. 93: 516-520, 1994
19. Malats, N., Porta, M., Pifiol, J. L., Corominas, J. M., Rifa, J., and Real, F. X. Ki-ras mutations as prognostic factor in extrahepatic bile system cancer. J. Clin. Oncol., 13: 1679-1686, 1995
20. Rosell, R., Mollzó, M., Pifarré, A., Ariza, A., Sánchez, J. J., Moreno, I., Maurel, J., López, M. P., Abad, A., and de Anta, J. M. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin. Cancer Res., 2: 1083-1086, 1996
21. Slebos, R. J. C., Kibbellar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderscheren, R. G. J. R. A., van Sandwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med., 323: 561-565, 1990
22. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989
23. Lane, D. P. p53 guardian of the genome. Nature (Lond.), 358: 15-16, 1992
24. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992
25. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991
26. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991
27. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., and Minna, J. D. p53: A frequent target for genetic abnormalities in lung cancer. Science (Wash. DC), 246: 491-494, 1989
28. Chiba, N., Takahashi, T., Nau, M. M., D'Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, K., Reissman, P. T., Slamon, D. J., Holmes, E. C., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990
29. Miller, C. W., Simon, K., Aslo, A., Kok, K., Yokota, J., Buys, C. H. C. M., Terada, M., and Koeffier, H. P. p53 mutations in human lung tumors. Cancer Res., 52: 1695-1698, 1992
30. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., Takahshi, T., and Ueda, R. p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res., 52: 734-736, 1992
31. Lechman, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. I., and Harris, C. C. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res., 51: 4090-4096, 1991
32. Kondo, K., Umemoto, A., Akimoto, S., Uyama, T., Hayashi, K., Ohnishi, Y., and Monden, Y. Mutations in the p53 tumour suppressor gene in primary lung cancer in Japan. Biochem. Biophys. Res. Commun., 183: 1139-1146, 1992
33. Nishio, M., Koshikawa, T., Kuroishi, T., Suyama, M., Uchida, K., Takagi, Y., Washimi, O., Sugiura, T., Ariyoshi, Y., Takahashi, T., and Ueda, R. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J. Clin. Oncol., 14: 497-502, 1996
34. Top, B., Mooi, W. J., Klaver, S. G., Boerrigter, L., Wisman, P., Elbers, H. R. J., Visser, S., and Rodenhuis, S. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int. J. Cancer, 64: 83-91, 1995
35. Bennett, W. P., Colby, T. V., Travis, W. D., Borkowski, A., Jones, R. T., Lane, D. P., Metcaf, R. A., Samet, J. M., Takeshima, Y., Gu, J. R., Vähäkangas, K. H., Soini, Y., Pääkkö, P., Welsh, J. A., Trump, B. F., and Harris, C. C. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res., 53: 4817-4822, 1993
36. Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani. C. T., Pastorino, U., Della Porta, G., and Pierotti, M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res., 52: 6079-6082. 1992
37. Hommura, F., Dosaka-Akita, H., Kinoshita, I., Mishina, T., Hiroumi, H., Ogura, S., Katoh, H., and Kawakami, Y. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br. J. Cancer, 81: 696-701, 1999
38. Ohsaki, Y., Tanno, S., Fujita, Y., Toyoshima, E., Fujiuchi, S., Nishigaki, Y., Ishida, S., Nagase, A., Miyokawa, N., Hirata, S., and Kikuchi. K. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep., 7: 603-607, 2000
39. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Nimi, T., Shimokata, K., Yamakawa, K., Nakamura, Y., and Ueda, R. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53: 1-4, 1993
40. Kawasaki, M., Nakanishi, Y., Kuwano, K., Yatsunami, J., Takayama, K., and Hara, N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin. Cancer Res., 3: 1195-1200, 1997
41. Ruddon, R. W. Causes of cancer. Cancer Biology, pp. 231-276. New York: Oxford University Press, 1995
42. Huberman, E., Sachs, L., Yang, S. K., and Gelboin, H. V. Identification of mutagenic metabolites of benzo(a)pyrene in mammalian cells. Proc. Natl. Acad. Sci. USA, 73: 607-611, 1976
43. Jerina, D. M., Yagi, H., Hernandez, O., Dansette, P. M., Wood, A. W., Levin, W., Chang, R. L., Wislocki, P. G., and Conney, A. G. Synthesis and biological activity of potential benzo[alpyrene metabolites. In: R. Frendenthal and P. W. Jones (eds.), Carcinogenesis: A Comprehensive Survey, pp. 91-113. New York: Raven Press, 1976
44. Weinstein, I. B., Jeffery, A. M., Jennette, K. W., Blobstein, S. H., Harvey, R. G., Harris, C., Antrup, H., Kasai, H., and Nakanishi, K. Benzo[a]pyrene diol epoxides as intermediates in nucleic acid binding in vitro and in vivo. Science (Wash. DC), 193: 592-595, 1976
45. Connery, A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons. Cancer Res., 42: 4875-4917, 1982
46. Meehan, T., and Straub, K. Double-stranded DNA stereoselectively binds benzo[a]pyrene diol epoxides. Nature (Lond.), 277: 410-412, 1979
47. Nakachi, K., Imai, K., Hayashi, S., and Kawajiri, K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res., 53: 2994-2999, 1993
48. Drakoulis, N., Cascorbi, I., Brockmoller, J., Gross, C. R., and Roots, I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: Exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin. Investig., 72: 240-248, 1994
49. Taioli, E., Crofts, F., Trachman, J., Demopoulos, R., Toniolo, P., and Garte, S. J. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res., 55: 472-473, 1995
50. Bartsch, H., Rojas, M., Nair, U., Nair, J., and Alexandrov, K. Genetic cancer susceptibility and DNA adducts: Studies in smokers, tobacco chewers, and coke oven workers. Cancer Detect. Prey., 23: 445-453, 1999
51. Grzybowska, E., Butkiewicz, D., Motykiewicz, G., and Chorazy, M. The effect of the genetic polymorphisms of CYP1A1, CYP2D6, GSTM1 and GSTP1 on aromatic DNA adduct levels in the population of healthy women. Mutat. Res., 469: 271-277, 2000
52. Schoket, B., Papp, G., Levay, K., Mrackova, G., Kadlubar, F. F., and Vincze, I. Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure. Mutat. Res., 482: 57-69, 2001
53. Smith, G. B. J., Harper, P. A., Wong, J. M. Y., Lam, M. S. M., Reid, K. R., Petsikas, D., and Massey, T. E. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: Impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol. Biomark. Prey., 10: 839-853, 2001
54. Butkiewicz, D., Grzybowska, E., Hemminki, K., Ovrebo, S., Haugen, A., Motykiewicz, G., and Chorazy, M. Modulation of DNA adduct levels in human mononuclear white blood cells and granulocytes by CYP1A1 CYP2D6 and GSTMI genetic polymorphisms. Mutat. Res., 415: 97-108, 1998
55. Butkiewicz, D., Grzybowska, E., Phillips, D. H., Hemminki, K., and Chorazy, M. Polymorphisms of the GSTP1 and GSTM1 genes and PAH-DNA adducts in human mononuclear white blood cells. Environ. Mol. Mutagen., 35: 99-105, 2000
56. Hou, S. M., Fait, S., Yang, K., Nyberg, F., Pershagen, G., Hemminki, K., and Lambert, B. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls. Cancer Epidemiol. Biomark. Prev., 10: 133-140, 2001
57. Reszka, E., and Wasowicz, W. Significance of genetic polymorphisms in glutathione S-transferase multigene family and lung cancer risk. Int. J. Occup. Med. Environ. Health, 14: 99-113, 2001
58. Knudsen, L. E., Loft, S. H., and Autrup, H. Risk assessment: The importance of genetic polymorphisms in man. Mutat. Res., 482: 83-88, 2001
59. Strange, R. C., Spiteri, M. A., Ramachandran, S., and Fryer, A. A. Glutathione-S-transferase family of enzymes. Mutat. Res., 482: 21-26, 2001
60. Hayashi, S., Watanabe, J., and Kawajiri, K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and μ-class glutathione S-transferase genes. Jpn. J. Cancer Res., 83: 866-870, 1992
61. Alexandrie, A. K., Sundberg, M. I., Seidegard, J., Tornling, G., and Rannug, A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis (Lond.), 15: 1785-1790, 1994
62. Kawajiri, K., Watanabe, J., and Hayashi, S. I. Identification of allelic variants of the human CYP1A1 gene. Methods Enzymol., 272: 226-232, 1996
63. Hayashi, S. I., Watanabe, J., Nakachi, K., and Kawajiri, K. Genetic linkage of lung cancer-associated Msp I polymorphisms with amino acid replacement in the heme binding region of the human P450IA1 gene. J. Biochem., 110: 407-411, 1991
64. Comstock, K. E., Sanderson, B. J. S., Claflin, G., and Henner, W. D. GST1 gene deletion determined by polymerase chain reaction. Nucleic Acids Res., 18: 3670-3670, 1990
65. Li, S., Rosell, R., Urban, A., Gont, A., Ariza, A., Armengol, P., Abad, A., Navas, J. J., and Monzo, M. K-ras gene point mutation: A stable tumor marker in non-small cell lung carcinoma. Lung Cancer, 11: 19-27, 1994
66. Behn, M., Qun, S., Pankow, W., Havemann, K., and Schuermann, M. Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based "enriched PCR" technique. Clin. Cancer Res., 4: 361-371, 1998
67. Mills, N. E., Fishman, C. L., Rom, W. N., Dubin, N., and Jacobson, D. R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma, Cancer Res., 55: 1444-1447, 1995
68. Boichot, E., Lagente, V., Mencia-Huerta, J. M., and Braquet, P. Broncho-pulmonary responses to to endothelin-1 in sensitized and challenged guinea-pigs: Role of cyclooxygenase metabolites and platelet-activating factor. Fundam. Clin. Pharmacol., 7: 281-291, 1993
69. Ridanpää, M., and Husgafvel-Pursiainen, K. Denaturing gradient gel electrophoresis (DGGE) assay for K-ras and N-ras genes: Detection of K-ras point mutations in human lung tumour DNA. Hum. Mol. Genet., 2: 639-644, 1993
70. Pellegata, N. S., Losekoot, M., Fodde, R., Pugliese, V., Saccomanno, S., Renault, B., Bernini, L. F., and Ranzani, G. N. Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): A study on pancreatic cancer. AntiCancer Res., 12: 1731-1735, 1992
71. Marion, M. J., Froment, O., and Trepo, C. Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol. Carcinog., 4: 450-454, 1991
72. Imai, M., Hoshi, T., and Ogawa, K. K-ras codon 12 mutations in bilary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. Cancer (Phila.), 73: 2727-2733, 1994
73. Span, M., Moerkerk, P. T. M., De Goeij, A. F. P. M., and Arends, J. W. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int. J. Cancer, 96: 241-245, 1996
74. Kastrinakis, W. V., Ramchurren, N., Maggard, M., Steele, G., Jr., and Summerhayes, I. C. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch. Surg., 130: 9-14, 1995
75. Stewart, J. H. I. Lung carcinoma in African Americans: A review of the current literature. Cancer (Phila.), 91: 2476-2482, 2001
76. Cooley, M. E., and Jennings-Dozier, K. Lung cancer in African Americans: A call to action. Cancer Practice, 6: 99-106, 1998
77. Pamies, R. J., and Woodard, L. J. Cancer in socioeconomically disadvantaged populations. Primary Care, 19: 443-450, 1992
78. Chen, V. W., Craig, J. F., Fontham, E. T. H., and Correa, P. Excessive cancer rates among blacks in Louisiana: An opportunity for physician intervention. J. LA State Med. Soc., 142: 18-26, 1992
79. Schwartz, R. S. Racial profiling in medical research. N. Engl. J, Med., 344: 1392-1393, 2001
80. Boffetta, P., Jourenkova, N., and Gustavsson, P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control, 8: 444-472, 1997
81. Hoffmann, D., Rivenson, A., and Hecht, S. S. The biological significance of tobacco-specific N-nitrosamines: Smoking and adenocarcinoma of the lung. Crit. Rev. Toxicol., 26: 199-211, 1996